Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
Vaxart reported Q3 2026 revenue of $10.6 million, down from $72.4 million in Q3 2025, with the net loss widening to $17.7 million ($0.07 per share) from $8.1 million ($0.04). Cash and short-term investments stand at $65.5 million with a runway only into Q2 2027, and the company says it is exploring partnerships and non-dilutive funding to extend it. Topline data from the ~5,400-participant Phase 2b COVID-19 trial is now expected by mid-year 2027, and Vaxart has received $278.0 million cumulatively under its BARDA contract. The company also received a European patent protecting its norovirus vaccine through at least 2036 and appointed retired Vice Admiral Dr.
Key figures
- Revenue
- 10600000
- Revenue Yoy
- -85%
- Net loss
- 17689000
- Ga expense
- 5074000
- Rd expense
- 22829000
- Cash runway
- into Q2 2027
- Prior year revenue
- $72.4 million
- Prior year net loss
- $8.1 million
- Cash and investments
- $65.5 million
- Phase 2b data timing
- mid-year 2027
- Barda cumulative payments
- $278.0 million
- Covid phase2b participants
- 400 sentinel + ~5,000 main cohort
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.